Header Logo

Connection

KENNETH R HESS to Brain Neoplasms

Back to Details
This is a "connection" page, showing publications KENNETH R HESS has written about Brain Neoplasms.
KENNETH R HESS
Connection Strength
2.282
Brain Neoplasms
  1. Clinical importance of eflornithine (a-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol. 2018 04; 7(2):CNS16.
    View in: PubMed
    Score: 0.190
  2. Glioblastoma resection. J Neurosurg. 2012 May; 116(5):1166-7; author reply 1167-8.
    View in: PubMed
    Score: 0.126
  3. Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer. 2007 Jun 22; 7:106.
    View in: PubMed
    Score: 0.091
  4. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol. 2006 May; 78(1):85-90.
    View in: PubMed
    Score: 0.082
  5. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004 Nov 15; 101(10):2293-9.
    View in: PubMed
    Score: 0.076
  6. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003 04; 5(2):89-95.
    View in: PubMed
    Score: 0.068
  7. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000 Oct; 6(10):3878-84.
    View in: PubMed
    Score: 0.057
  8. Response and progression in recurrent malignant glioma. Neuro Oncol. 1999 10; 1(4):282-8.
    View in: PubMed
    Score: 0.053
  9. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol. 1999 May; 42(3):227-31.
    View in: PubMed
    Score: 0.052
  10. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433.
    View in: PubMed
    Score: 0.050
  11. Assessing response to chemotherapy in malignant glioma: the role of steroids. Neurology. 1998 Apr; 50(4):1197; disscussion 1197-8.
    View in: PubMed
    Score: 0.048
  12. Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy. J Neurooncol. 2018 Mar; 137(1):57-65.
    View in: PubMed
    Score: 0.047
  13. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2253-61.
    View in: PubMed
    Score: 0.047
  14. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol. 2017 10; 125(1):80-88.
    View in: PubMed
    Score: 0.046
  15. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048.
    View in: PubMed
    Score: 0.046
  16. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017 06 01; 19(6):786-795.
    View in: PubMed
    Score: 0.045
  17. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncol. 2017 05 01; 19(5):660-668.
    View in: PubMed
    Score: 0.045
  18. Survival after radiosurgery for brain metastasis: regarding Buatti et al. IJROBP 32(4):1161-1166; 1995. Int J Radiat Oncol Biol Phys. 1996 Sep 01; 36(2):523.
    View in: PubMed
    Score: 0.043
  19. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52.
    View in: PubMed
    Score: 0.041
  20. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol. 2015 May; 123(1):141-50.
    View in: PubMed
    Score: 0.039
  21. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015 May; 20(5):466-73.
    View in: PubMed
    Score: 0.039
  22. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73.
    View in: PubMed
    Score: 0.038
  23. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol. 2014 Jun; 16(6):823-8.
    View in: PubMed
    Score: 0.036
  24. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014 Jan; 16(1):81-91.
    View in: PubMed
    Score: 0.036
  25. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):449-55.
    View in: PubMed
    Score: 0.033
  26. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012 Jul 15; 118(14):3599-606.
    View in: PubMed
    Score: 0.031
  27. EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer. 2011 Sep 28; 10:123.
    View in: PubMed
    Score: 0.031
  28. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov; 10(11):1037-44.
    View in: PubMed
    Score: 0.027
  29. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008 Oct; 90(1):89-97.
    View in: PubMed
    Score: 0.024
  30. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008 Apr; 10(2):216-22.
    View in: PubMed
    Score: 0.024
  31. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15; 13(24):7401-6.
    View in: PubMed
    Score: 0.024
  32. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6603-9.
    View in: PubMed
    Score: 0.023
  33. Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J. 2007 Sep; 21(11):2918-30.
    View in: PubMed
    Score: 0.023
  34. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7.
    View in: PubMed
    Score: 0.022
  35. Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J Pain Symptom Manage. 2006 Aug; 32(2):148-54.
    View in: PubMed
    Score: 0.021
  36. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst. 2006 May 03; 98(9):625-36.
    View in: PubMed
    Score: 0.021
  37. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol. 2006 Oct; 80(1):83-90.
    View in: PubMed
    Score: 0.021
  38. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93.
    View in: PubMed
    Score: 0.021
  39. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005 Oct 01; 104(7):1468-77.
    View in: PubMed
    Score: 0.020
  40. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol. 2005 Oct; 7(4):485-94.
    View in: PubMed
    Score: 0.020
  41. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61.
    View in: PubMed
    Score: 0.020
  42. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35.
    View in: PubMed
    Score: 0.019
  43. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9.
    View in: PubMed
    Score: 0.019
  44. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol. 2004 Jul; 6(3):253-8.
    View in: PubMed
    Score: 0.019
  45. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer. 2004 Apr 15; 100(8):1712-6.
    View in: PubMed
    Score: 0.018
  46. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):212-21.
    View in: PubMed
    Score: 0.018
  47. O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol. 2004 Jan; 6(1):28-32.
    View in: PubMed
    Score: 0.018
  48. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):33-7.
    View in: PubMed
    Score: 0.018
  49. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):44-54.
    View in: PubMed
    Score: 0.018
  50. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res. 2003 Mar; 9(3):981-90.
    View in: PubMed
    Score: 0.017
  51. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology. 2003; 65(3):259-66.
    View in: PubMed
    Score: 0.017
  52. Identification of combination gene sets for glioma classification. Mol Cancer Ther. 2002 Nov; 1(13):1229-36.
    View in: PubMed
    Score: 0.017
  53. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys. 2002 May 01; 53(1):58-66.
    View in: PubMed
    Score: 0.016
  54. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol. 2002 Apr; 4(2):109-14.
    View in: PubMed
    Score: 0.016
  55. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002 Mar 01; 20(5):1383-8.
    View in: PubMed
    Score: 0.016
  56. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 2002 Jan; 12(1):108-16.
    View in: PubMed
    Score: 0.016
  57. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest. 2002; 20(7-8):948-54.
    View in: PubMed
    Score: 0.016
  58. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001 Aug; 95(2):190-8.
    View in: PubMed
    Score: 0.015
  59. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol. 2001 07; 3(3):167-73.
    View in: PubMed
    Score: 0.015
  60. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000 Feb; 18(3):646-50.
    View in: PubMed
    Score: 0.014
  61. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1999 Aug 01; 45(1):127-35.
    View in: PubMed
    Score: 0.013
  62. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999 Aug; 17(8):2572-8.
    View in: PubMed
    Score: 0.013
  63. Gamma-ray mutagen sensitivity and survival in patients with glioma. Clin Cancer Res. 1998 Dec; 4(12):3031-5.
    View in: PubMed
    Score: 0.013
  64. Ependymomas: MIB-1 proliferation index and survival. J Neurooncol. 1998 Oct; 40(1):51-7.
    View in: PubMed
    Score: 0.012
  65. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998 May; 42(5):1044-55; discussion 1055-6.
    View in: PubMed
    Score: 0.012
  66. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology. 1998 Mar; 50(3):777-81.
    View in: PubMed
    Score: 0.012
  67. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 1997 Mar; 15(3):1063-70.
    View in: PubMed
    Score: 0.011
  68. Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg. 1996 May; 84(5):748-54.
    View in: PubMed
    Score: 0.011
  69. Reoperation for recurrent metastatic brain tumors. J Neurosurg. 1995 Oct; 83(4):600-4.
    View in: PubMed
    Score: 0.010
  70. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003 Aug 15; 9(9):3369-75.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.